Objective To evaluate the clinical application of fluorescent quantification polymerase chain reaction {FQ-PCR) for combined detection of C-erbB2, c-myc and CCND1 mKNA levels in breast cancer. Methods We used β-microprotein mRNA as internal control, four mRNA in peripheral blood samples from 15 health women, 30 patients with benign breast disease and 81 patients with breast carcinoma were detected by FQ-PCR. Results While no significant difference in four mRNA levels was found between normal controls and benign breast disease group ( P >0. 05). Three mRNA levels in breast cancer group were higher than those in the other groups (P<0. 05). No difference was found in β2-microglobin among three groups (P>0. 05). The sensitivity of three mRNA levels by combined detection was higher than that of single gene detection. Conclusions FQ-PCR method is better for detecting C-erbB2 and c-myc and CCND1 mRNA levels for its sensitivity and specificity. The sensitivity of diagnosis for breast cancer can be improved by combined detection.%目的 建立荧光定量聚合酶链反应(FQ-PCR)法检测C-erbB2、核内原癌基因(c-myc)和细胞周期蛋白D1(CC-ND1)mRNA水平,探讨其联合检测在乳腺癌诊断和治疗监测中的应用.方法 建立FQ-PCR法,并以β2-微球蛋白为内对照测定15名健康女性体检者(正常对照组)、30例良性乳腺疾病患者(良性乳腺疾病组)和121例乳腺癌患者(乳腺癌组)外周血中C-erbB2、c-myc和CCNDI的mRNA水平.结果 C-erbB2、c-myc和CCND1的mRNA水平在正常对照组和良性乳腺疾病组间差异无统计学意义(P>0.05),乳腺癌组均高于前两组(P<0.05),β2-微球蛋白三组间差异无统计学意义(P>0.05);三种mRNA联合检测的阳性率高于单个mRNA的检测.结论 FQ-PCR技术可快速定量检测C-erbB2、c-myc和CCNDI的mR-NA,三者联合检测可有效提高对乳腺癌诊断的阳性率.
展开▼
